MindMed

Ann Arbor Votes To Decriminalize Entheogenic Plants and Fungi The city of Ann Arbor in Michigan voted in favor of the decriminalization of natural psychedelics, including Psilocybe Mushrooms, Ayahuasca, the Peyote Cacti and the Iboga Plant, among others. The resolution does not legalize the...

Psychedelic drug development company MindMed (NEO: MMED) (OTCQB: MMEDF) has submitted an application to cross-list on NASDAQ. MindMed was the first psychedelics company to go public in March of 2020 on the NEO exchange. The company also lists on the Frankfurt Stock Exchange under the symbol...

Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol...

FDA Expands Psychiatric Indications For Nasal Spray Ketamine Last week, the FDA approved suicidal tendencies as additional qualifying symptoms for the application of Spravato, a ketamine nasal spray used in psychiatric treatment. Spravato is the brand name for esketamine, a chemical sibling of...

Biopharmaceutical and psychedelics research company Mind Medicine Inc. (NEO:MMED) (OTC: MMEDF)  announced Thursday that it will begin studying DMT’s effects on humans in a Phase 1 clinical trial conducted in collaboration with University Hospital Basel in Switzerland. Understanding The...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. New Leaf Brands Changes Name To Mydecine, Announces New HQ  Cannabis company NewLeaf...

Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline. The move comes as part of the company’s exclusive collaboration agreement with the University...

The COVID-19 coronavirus has prompted mass business closures, leading some economic forecasters to suggest 50 million jobs may be vulnerable to permanent layoffs, a scenario that may fuel the emergence of a mental health catastrophe. In a bid to address the arrival of a national health crisis, Mind...

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel. Exploring High-Dose LSD...

Welcome to the first edition of Psyched, a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. MindMed Became the First Psychedelics Company to List...

I’ve been telling investors for over a year now that when the first psychedelics pure play goes public, it’s going to crush it. And that’s exactly what happened. This week, MindMed (OTC: MMEDF) went public on the NEO exchange, and also in the U.S. with an OTC listing, trading...